SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001798749-24-000014
Filing Date
2024-03-25
Accepted
2024-03-25 16:12:59
Documents
15
Period of Report
2024-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20240325x8k.htm   iXBRL 8-K 42149
2 EX-99.1 tmb-20240325xex99d1.htm EX-99.1 105031
3 GRAPHIC tmb-20240325xex99d1001.jpg GRAPHIC 5633
  Complete submission text file 0001798749-24-000014.txt   290792

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20240325.xsd EX-101.SCH 3124
5 EX-101.LAB tmb-20240325_lab.xml EX-101.LAB 16578
6 EX-101.PRE tmb-20240325_pre.xml EX-101.PRE 10780
18 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240325x8k_htm.xml XML 5040
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 24779343
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)